证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》。公司拟在"益丰数字化平台升级项目"实施期间以不超过705.00万元募集资金等额置 换自有资金先行支付的相关支出，该部分等额置换资金视同募投项目使用资金。本次募集资金等额置换 的事项无需提交股东会审议。 （编辑 任世碧） ...

（编辑 任世碧） 证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于部分募集资金投资项目延期的议案》，同意将募集 资金投资项目"益丰数字化平台升级项目"的建设完成日期延长至2025年12月31日。 ...

（文章来源：证券日报） 证券日报网讯 7月30日晚间，益丰药房发布公告称，公司第五届董事会第十九次会议审议通过了《关于 取消监事会并修订的议案》等多项议案。 ...

Group 1 - The company held its fourth supervisory board meeting, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to temporarily use part of the idle raised funds to supplement working capital, which is expected to enhance fund utilization efficiency and reduce financial costs [1][2] - The decision to use idle funds does not affect the normal implementation of investment projects and is in the interest of the company and all shareholders [1]

Core Points - The company announced a cash dividend distribution of 0.08 yuan per share for the fiscal year 2024, approved at the shareholders' meeting on June 30, 2025 [2][4] - The total cash dividend to be distributed amounts to approximately 60.81 million yuan, based on a total share capital of 760,095,613 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [3] Distribution Plan - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [5] - The distribution does not involve the issuance of bonus shares or capital increases [6] - Direct cash dividends will be issued to specific shareholders, including Lao Bai Xing Medical Group Co., Ltd., Zexing Investment Co., Ltd., and Chen Xiulan [9] Taxation Details - For individual shareholders and securities investment funds holding unrestricted circulating shares, no income tax will be withheld at the time of dividend distribution, with the actual cash dividend being 0.08 yuan per share [10] - Tax liabilities will be calculated based on the holding period of the shares, with different tax rates applicable: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.072 yuan per share [11]

Summary of Key Points Core Viewpoint The announcements from Yifeng Pharmacy Chain Co., Ltd. detail the status of its convertible bonds and the management of idle raised funds through financial products, indicating a strategic approach to enhance financial efficiency and shareholder returns. Group 1: Convertible Bond Conversion Status - As of June 30, 2025, a total face value of 163,000 yuan of "Yifeng Convertible Bonds" has been converted into 4,950 shares of the company's A-shares, representing 0.0004% of the total shares before conversion [2][4]. - The remaining unconverted "Yifeng Convertible Bonds" have a face value of 1,797,269,000 yuan, accounting for 99.9909% of the total issuance [2][4]. - During the quarter from April 1, 2025, to June 30, 2025, 2,000 yuan of "Yifeng Convertible Bonds" were converted into 60 shares [2][4]. Group 2: Convertible Bond Issuance Overview - The company issued 17,974,320 convertible bonds with a total face value of 179,743.20 million yuan, approved by the China Securities Regulatory Commission on March 4, 2024 [3]. - The bonds were listed on the Shanghai Stock Exchange on March 27, 2024, and can be converted into shares starting from September 9, 2024 [3]. Group 3: Management of Idle Funds - The company redeemed structured deposits totaling 10,300.00 million yuan and plans to continue investing 11,400.00 million yuan in new financial products [6][8]. - The board approved the use of up to 30,000.00 million yuan of idle raised funds for financial investments, ensuring that it does not affect the normal operation of investment projects [6][10]. - The investment strategy aims to enhance the efficiency of idle funds and increase company returns without impacting daily operations [13].

Core Viewpoint - The credit rating for Yifeng Pharmacy's convertible bonds remains stable at "AA," with no changes from the previous rating [1]. Group 1 - The previous rating for the convertible bonds was "AA," and the issuer's rating was also "AA," with a stable outlook [1]. - The current rating results for both the issuer and the convertible bonds are unchanged from the last assessment [1]. - The credit rating agency, United Credit Ratings Co., conducted a comprehensive analysis of the company's operational status and industry conditions for this tracking rating [1]. Group 2 - The tracking credit rating report for the convertible bonds can be found on the Shanghai Stock Exchange website [2]. - The announcement is made by the board of directors of Yifeng Pharmacy [3].

Group 1 - The issuer of the convertible bonds is Yifeng Pharmacy Chain Co., Ltd., with a total issuance amount of RMB 1,797.43 million, net proceeds after issuance costs amounting to RMB 1,780.26 million [2][3][14] - The bonds have a maturity period of six years, from March 4, 2024, to March 3, 2030, with a face value of RMB 100 per bond [3][4] - The coupon rates for the bonds are set at 0.30% for the first year, 0.50% for the second year, and 1.00% for the third year [4][5] Group 2 - The initial conversion price for the bonds is set at RMB 39.85 per share, subject to adjustments based on various corporate actions [5][6] - The conversion price will be adjusted to RMB 32.79 per share effective from June 7, 2024, due to the company's annual profit distribution [7][8] - Further adjustments will reduce the conversion price to RMB 32.54 per share effective from October 15, 2024, and to RMB 32.14 per share effective from June 18, 2025 [8][19] Group 3 - The total amount raised from the bond issuance will be used for projects including the construction of pharmaceutical warehouses in Jiangsu, Hubei, and Hebei, with a total investment of RMB 2,534.33 million [14][15] - The bonds are rated AA by a credit rating agency, with a stable outlook, and the issuer's credit rating is also maintained at AA [16][17] - The bonds will not be secured, and the management of the raised funds will be conducted in a designated special account [15][16] Group 4 - The actual controller and major shareholders have reduced their holdings of the convertible bonds, with a total of 5,259,730 bonds sold, representing 29.26% of the total issuance [20][21] - The company has also repurchased and canceled a portion of restricted stock from its 2022 incentive plan, which does not affect the conversion price of the bonds [21][22] - The company will continue to monitor the impact of these actions on its operational performance and debt repayment capabilities [22]

Core Viewpoint - Yifeng Pharmacy (603939) announced that Huxin Chuangtou, Yizhi Feng, and Yiren Tang plan to collectively reduce their holdings by no more than 2% of the company's shares [1] Group 1 - The total planned reduction in shareholding is capped at 2% [1]

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of its 2024 annual equity distribution plan, resulting in a decrease from 32.54 CNY to 32.14 CNY per share [1][3]. Group 1: Bond Information - The convertible bond, referred to as "益丰转债," was publicly issued on March 4, 2024, and listed on the Shanghai Stock Exchange on March 27, 2024 [1]. - The bond has a maturity period of 6 years, from March 4, 2024, to March 3, 2030, with a conversion period from September 8, 2024, to March 3, 2030 [1]. Group 2: Equity Distribution Details - The company plans to distribute a cash dividend of 0.40 CNY per share (including tax) to all shareholders, with the record date set for June 17, 2025, and the ex-dividend date on June 18, 2025 [2]. - The adjustment to the conversion price is based on the company's equity distribution plan, which includes provisions for adjusting the conversion price in the event of cash dividends, stock dividends, or other equity changes [2]. Group 3: Conversion Price Adjustment - The conversion price adjustment formula is specified in the company's prospectus, detailing how the price will be recalculated based on various equity distribution scenarios [2]. - The adjusted conversion price of 32.14 CNY per share will take effect on June 18, 2025, following the equity distribution [3]. - The convertible bonds will be suspended from conversion from June 11, 2025, to June 17, 2025, and will resume conversion on June 18, 2025 [3].